TR201906117T4 - Nitrokatesollere yönelik uygulama rejimi. - Google Patents

Nitrokatesollere yönelik uygulama rejimi. Download PDF

Info

Publication number
TR201906117T4
TR201906117T4 TR2019/06117T TR201906117T TR201906117T4 TR 201906117 T4 TR201906117 T4 TR 201906117T4 TR 2019/06117 T TR2019/06117 T TR 2019/06117T TR 201906117 T TR201906117 T TR 201906117T TR 201906117 T4 TR201906117 T4 TR 201906117T4
Authority
TR
Turkey
Prior art keywords
nitrocatalyls
application regime
regime
application
substituents
Prior art date
Application number
TR2019/06117T
Other languages
English (en)
Inventor
Luis De Almeida Jose
Alexander Learmonth David
Manuel Vieira Araujo Soares Da Silva Patricio
Original Assignee
Bial Portela & Ca Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bial Portela & Ca Sa filed Critical Bial Portela & Ca Sa
Publication of TR201906117T4 publication Critical patent/TR201906117T4/tr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4245—Oxadiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2009—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4858—Organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Psychology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Inorganic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Steroid Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)

Abstract

Mevcut buluş, formülün (I) bileşiklerine yönelik yeni doz rejimleri ile ilgilidir: burada sübstitüeler tarifnamede belirtildiği gibidir.
TR2019/06117T 2008-07-29 2009-07-29 Nitrokatesollere yönelik uygulama rejimi. TR201906117T4 (tr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US13724808P 2008-07-29 2008-07-29

Publications (1)

Publication Number Publication Date
TR201906117T4 true TR201906117T4 (tr) 2019-05-21

Family

ID=41130570

Family Applications (1)

Application Number Title Priority Date Filing Date
TR2019/06117T TR201906117T4 (tr) 2008-07-29 2009-07-29 Nitrokatesollere yönelik uygulama rejimi.

Country Status (17)

Country Link
US (1) US20110301204A1 (tr)
EP (1) EP2307020B1 (tr)
JP (2) JP6165412B2 (tr)
KR (3) KR20180095135A (tr)
CN (1) CN102355900A (tr)
AR (1) AR072846A1 (tr)
AU (1) AU2009277196B2 (tr)
BR (1) BRPI0913913A2 (tr)
CA (1) CA2729288C (tr)
DK (1) DK2307020T3 (tr)
ES (1) ES2723729T3 (tr)
IL (1) IL210393A0 (tr)
MX (2) MX360330B (tr)
PT (1) PT2307020T (tr)
RU (1) RU2557532C2 (tr)
TR (1) TR201906117T4 (tr)
WO (1) WO2010014025A1 (tr)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2007013830A1 (en) 2005-07-26 2007-02-01 Portela & Ca. S.A. Nitrocatechol derivatives as comt inhibitors
EP1845097A1 (en) 2006-04-10 2007-10-17 Portela & Ca., S.A. Oxadiazole derivatives as COMT inhibitors
RU2518483C2 (ru) 2007-01-31 2014-06-10 Биал-Портела Энд Ка, С.А. Режим дозирования ингибиторов комт
CN102015696A (zh) 2008-03-17 2011-04-13 比艾尔-坡特拉有限公司 5-[3-(2，5-二氯-4，6-二甲基-1-氧吡啶-3-基)-[1，2，4]噁二唑-5-基]-3-硝基苯-1，2-二醇的晶型
DK2413912T3 (da) 2009-04-01 2019-06-17 Bial Portela & Ca Sa Farmaceutiske formuleringer, der omfatter nitrocatecholderivater, og metoder til fremstilling deraf
WO2011069075A2 (en) * 2009-12-04 2011-06-09 Grant Jon E Treating impulse control disorders with catechol-o- methyl-transferase inhibitors
US20140045900A1 (en) * 2011-02-11 2014-02-13 Bial-Portela & Ca, S.A. Administration regime for nitrocatechols
PL2791134T3 (pl) 2011-12-13 2020-03-31 BIAL - PORTELA & Cª S.A. Związek chemiczny użyteczny jako związek pośredni do wytwarzania inhibitora katechol-o-metylotransferazy
RU2017120184A (ru) 2014-11-28 2018-12-28 БИАЛ - ПОРТЕЛА ЭНД Ка, С.А. Лекарства для замедления течения болезни паркинсона
US12097193B2 (en) 2018-10-05 2024-09-24 Bial—Portela & Ca, S.A. Methods for the administration of COMT inhibitors

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE10338174A1 (de) * 2003-08-20 2005-03-24 Lts Lohmann Therapie-Systeme Ag Transdermale Arzneimittelzubereitungen mit Wirkstoffkombinationen zur Behandlung der Parkinson-Krankheit
US20060173074A1 (en) * 2004-11-10 2006-08-03 Juha Ellmen Treatment of restless legs syndrome
KR20080027463A (ko) * 2005-05-18 2008-03-27 아덱스 파마 에스에이 대사성 글루타메이트 수용체의 양성 알로스테릭조절자로서의 치환된 옥사디아졸 유도체
WO2007013830A1 (en) * 2005-07-26 2007-02-01 Portela & Ca. S.A. Nitrocatechol derivatives as comt inhibitors
EP1845097A1 (en) * 2006-04-10 2007-10-17 Portela & Ca., S.A. Oxadiazole derivatives as COMT inhibitors
RU2518483C2 (ru) * 2007-01-31 2014-06-10 Биал-Портела Энд Ка, С.А. Режим дозирования ингибиторов комт
CN102015696A (zh) * 2008-03-17 2011-04-13 比艾尔-坡特拉有限公司 5-[3-(2，5-二氯-4，6-二甲基-1-氧吡啶-3-基)-[1，2，4]噁二唑-5-基]-3-硝基苯-1，2-二醇的晶型

Also Published As

Publication number Publication date
AR072846A1 (es) 2010-09-22
IL210393A0 (en) 2011-03-31
WO2010014025A1 (en) 2010-02-04
MX2011001046A (es) 2011-03-29
JP2015129163A (ja) 2015-07-16
AU2009277196B2 (en) 2015-06-18
CA2729288A1 (en) 2010-02-04
JP6165412B2 (ja) 2017-07-19
RU2010154173A (ru) 2012-09-10
ES2723729T3 (es) 2019-08-30
JP2011529489A (ja) 2011-12-08
MX360330B (es) 2018-10-30
KR20190079705A (ko) 2019-07-05
BRPI0913913A2 (pt) 2015-10-13
KR20110044949A (ko) 2011-05-03
EP2307020A1 (en) 2011-04-13
AU2009277196A1 (en) 2010-02-04
RU2557532C2 (ru) 2015-07-20
KR20180095135A (ko) 2018-08-24
DK2307020T3 (da) 2019-05-13
CN102355900A (zh) 2012-02-15
US20110301204A1 (en) 2011-12-08
JP6518080B2 (ja) 2019-05-22
PT2307020T (pt) 2019-05-28
CA2729288C (en) 2017-01-17
EP2307020B1 (en) 2019-02-20

Similar Documents

Publication Publication Date Title
TR201906117T4 (tr) Nitrokatesollere yönelik uygulama rejimi.
CY1119515T1 (el) Οξαζολο υποκατεστημενα ινδαζολια ως αναστολεις ρι3-κινασης
MX2010009416A (es) Compuestos heterociclicos como inhibidores de cxcr2.
MY160490A (en) Arylethynyl derivatives
BR112014030473A2 (pt) novo diazaespirocicloalcano e azaespirocicloalcano
CO6321282A2 (es) Derivados de piperidinilindol como inhibidores de aldosterona sintasa
BR112015004111A2 (pt) novos derivados bicíclicos
PH12014502169A1 (en) N-cyclylamides as nematicides
UA114087C2 (xx) Похідні піридину
MY169043A (en) New dihydroquinoline-2-one derivatives
TR201903981T4 (tr) Kanser tedavisi için bileşikler.
EA201291317A1 (ru) Тетрагидропиридопиримидиновые производные
ATE427927T1 (de) Phenylacetylenderivate mit affinitat zum mglur5- rezeptor
DE602006009789D1 (de) Acetylenderivate
BRPI0812222A2 (pt) Compostos ciclobutenodiona substituídos anti-inflamatórios.
UA110600C2 (uk) Спосіб отримання захищених похідних l-аланіну
EA201490846A1 (ru) Новые производные арилхинолина
SV2011003800A (es) Derivados de piridino-piridinonas, su preparacion y su aplicacion en terapeutica
EA201101148A1 (ru) Новые гербициды
UA106880C2 (uk) Нові гербіциди
EA201101146A1 (ru) Новые гербициды
EA200900090A1 (ru) Бензиламины, способ их получения и их применение в качестве противовоспалительных средств
EA201270256A1 (ru) Производные т1-замещенного 5-фтор-2-оксопиримидинон-1 (2h) -карбоксамида
CR20130431A (es) 5-(fenil)/piridinil-etinil)-2-piridina/ 2-pirimidina-carboxamidas como moduladores de mglur5
NO20081207L (no) Isoquinolines as IGF-1R inhibitors